Trichostatin A suppresses EGFR expression through induction of microRNA-7 in an HDAC-independent manner in lapatinib-treated cells

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Tu, Chih Yen ^a,b,c   Chen, Chia Hung ^a   Hsia, Te Chun ^a   Hsu, Min Hsiang ^a   Wei, Ya Ling ^a   Yu, Meng Chieh ^a   Chen, Wen Shu ^a,d   Hsu, Ke Wei ^a   Yeh, Ming Hsin ^a   Liu, Liang Chih ^a,b   Chen, Yun Ju ^e,f   Huang, Wei Chien ^a,g  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^e E DA HOSPITAL   (Taiwan)

^f I SHOU UNIVERSITY   (Taiwan)

^g ASIA UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 4; HISTONE DEACETYLASE 5; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE 7; HISTONE H2B; LAPATINIB; LONG UNTRANSLATED RNA; MICRORNA; MICRORNA 7; SINGLE STRANDED RNA; SMALL INTERFERING RNA; TRICHOSTATIN A; UNCLASSIFIED DRUG; VORINOSTAT; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; HISTONE DEACETYLASE; HYDROXAMIC ACID; MESSENGER RNA; MIRN7 MICRORNA, HUMAN; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

3' UNTRANSLATED REGION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CELL MIGRATION; CONTROLLED STUDY; ENDOCYTOSIS; ENZYME INHIBITION; GENE EXPRESSION; HISTONE ACETYLATION; HUMAN; HUMAN CELL; HYPOPHYSIS; LONG TERM CARE; PROTEIN BLOOD LEVEL; TRIPLE NEGATIVE BREAST CANCER; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; MICRORNAS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA, MESSENGER; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84897838897     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/168949     Document Type: Article

References (50)

1. Slamon D. J., Clark G. M., Wong S. G., Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987 235 4785 177 182 2-s2.0-0023084858 (Pubitemid 17231334)
2. Slamon D. J., Godolphin W., Jones L. A., Holt J. A., Wong S. G., Keith D. E., Levin W. J., Stuart S. G., Udove J., Ullrich A., Press M. F., Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989 244 4905 707 712 2-s2.0-0024337144 (Pubitemid 19147683)
3. Hynes N. E., Lane H. A., ERBB receptors and cancer: the complexity of targeted inhibitors. Nature Reviews Cancer 2005 5 5 341 354 2-s2.0-18344390418 10.1038/nrc1609 (Pubitemid 40637826)
4. Guy C. T., Cardiff R. D., Muller W. J., Activated neu induces rapid tumor progression. Journal of Biological Chemistry 1996 271 13 7673 7678 2-s2.0-0029997433 10.1074/jbc.271.13.7673 (Pubitemid 26107049)
5. Herbst R. S., Review of epidermal growth factor receptor biology. International Journal of Radiation Oncology Biology Physics 2004 59 supplement 2 21 26 10.1016/j.ijrobp.2003.11.041 (Pubitemid 38610223)
6. Rusnak D. W., Affleck K., Cockerill S. G., Stubberfield C., Harris R., Page M., Smith K. J., Guntrip S. B., Carter M. C., Shaw R. J., Jowett A., Stables J., Topley P., Wood E. R., Brignola P. S., Kadwell S. H., Reep B. R., Mullin R. J., Alligood K. J., Keith B. R., Crosby R. M., Murray D. M., Knight W. B., Gilmer T. M., Lackey K., The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer. Cancer Research 2001 61 19 7196 7203 2-s2.0-0035476866 (Pubitemid 32946515)
7. Rusnak D. W., Lackey K., Affleck K., Wood E. R., Alligood K. J., Rhodes N., Keith B. R., Murray D. M., Knight W. B., Mullin R. J., Gilmer T. M., The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Molecular Cancer Therapeutics 2001 1 2 85 94 2-s2.0-0035553174
8. Johnston S., Pippen J. Jr., Pivot X., Lichinitser M., Sadeghi S., Dieras V., Gomez H. L., Romieu G., Manikhas A., Kennedy M. J., Press M. F., Maltzman J., Florance A., O'Rourke L., Oliva C., Stein S., Pegram M., Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. Journal of Clinical Oncology 2009 27 33 5538 5546 2-s2.0-73149115341 10.1200/JCO.2009.23. 3734
9. Amir E., Ocaña A., Seruga B., Freedman O., Clemons M., Lapatinib and HER2 status: results of a meta-analysis of randomized phase III trials in metastatic breast cancer. Cancer Treatment Reviews 2010 36 5 410 415 2-s2.0-77955096969 10.1016/j.ctrv.2009.12.012
10. Boussen H., Cristofanilli M., Zaks T., DeSilvio M., Salazar V., Spector N., Phase II study to evaluate the efficacy and safety of neoadjuvant lapatinib plus paclitaxel in patients with inflammatory breast cancer. Journal of Clinical Oncology 2010 28 20 3248 3255 2-s2.0-77954745034 10.1200/JCO.2009.21.8594
11. Burstein H. J., Storniolo A. M., Franco S., Forster J., Stein S., Rubin S., Salazar V. M., Blackwell K. L., A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer. Annals of Oncology 2008 19 6 1068 1074 2-s2.0-44849108294 10.1093/annonc/mdm601 (Pubitemid 351796331)
12. Downey L., Livingston R. B., Koehler M., Arbushites M., Williams L., Santiago A., Guzman R., Villalobos I., Leo A. D., Press M. F., Chromosome 17 polysomy without human epidermal growth factor receptor 2 amplification does not predict response to lapatinib plus paclitaxel compared with paclitaxel in metastatic breast cancer. Clinical Cancer Research 2010 16 4 1281 1288 2-s2.0-76749105328 10.1158/1078-0432.CCR-09-1643
13. Finn R. S., Gagnon R., Di Leo A., Press M. F., Arbushites M., Koehler M., Prognostic and predictive value of HER2 extracellular domain in metastatic breast cancer treated with lapatinib and paclitaxel in a randomized phase III study. Journal of Clinical Oncology 2009 27 33 5552 5558 2-s2.0-73949125361 10.1200/JCO.2008.21.1763
14. Finn R. S., Press M. F., Dering J., Arbushites M., Koehler M., Oliva C., Williams L. S., Di Leo A., Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatment in HER2-negative or unknown metastatic breast cancer. Journal of Clinical Oncology 2009 27 24 3908 3915 2-s2.0-69849105168 10.1200/JCO.2008.18.1925
15. Frassoldati A., Guarneri V., Piacentini F., Jovic G., Giovannelli S., Oliva C., Conte P. F., Letrozole versus letrozole plus lapatinib (GW572016) in hormone-sensitive, HER2-negative operable breast cancer: a double-blind, randomized, phase II study with biomarker evaluation (EGF109077-LAP107692/ LETLOB). Clinical Breast Cancer 2008 8 1 97 100 2-s2.0-40449112910 10.3816/CBC.2008.n.010 (Pubitemid 351346237)
16. Toi M., Iwata H., Fujiwara Y., Ito Y., Nakamura S., Tokuda Y., Taguchi T., Rai Y., Aogi K., Arai T., Watanabe J., Wakamatsu T., Katsura K., Ellis C. E., Gagnon R. C., Allen K. E., Sasaki Y., Takashima S., Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety, and biomarker results from Japanese patients phase II studies. British Journal of Cancer 2009 101 10 1676 1682 2-s2.0-70449517339 10.1038/sj.bjc. 6605343
17. Siziopikou K. P., Ariga R., Proussaloglou K. E., Gattuso P., Cobleigh M., The challenging estrogen receptor-negative/progesterone receptor-negative/HER- 2-negative patient: a promising candidate for epidermal growth factor receptor-targeted therapy? Breast Journal 2006 12 4 360 362 2-s2.0-33745590399 10.1111/j.1075-122X.2006.00276.x (Pubitemid 43989982)
18. Siziopikou K. P., Cobleigh M., The basal subtype of breast carcinomas may represent the group of breast tumors that could benefit from EGFR-targeted therapies. Breast 2007 16 1 104 107 2-s2.0-33846587923 10.1016/j.breast.2006.09. 003 (Pubitemid 46172864)
19. Chen Y. J., Yeh M. H., Yu M. C., Wei Y. L., Chen W. S., Chen J. Y., Shih C. Y., Tu C. Y., Chen C. H., Hsia T. C., Lapatinib-induced NF-kappaB activation sensitizes triple-negative breast cancer cells to proteasome inhibitors. Breast Cancer Research 2013 15 6, article R108 10.1186/bcr3575
20. Huang W. C., Chen Y. J., Hung M. C., Implication of nuclear EGFR in the development of resistance to anticancer therapies. Biomedicine 2011 1 1 2 10 2-s2.0-80155202861 10.1016/j.biomed.2011.10.001
21. Sharma P., Lapatinib in Women with Metastatic Breast Cancer Who Have Failed Prior Antihormone Therapy 2000 NLM Identifier: NCT00759642 Bethesda, Md, USA U.S. National Library of Medicine. http://clinicaltrials.gov/show/ NCT00759642
22. Dhillon N., A Study of Lapatinib in Combination with Everolimus in Patients with Advanced, Triple Negative Breast Cancer 2000 NLM Identifier: NCT01272141 Bethesda, Md, USA U.S. National Library of Medicine. http://clinicaltrials.gov/show/NCT01272141
23. Hsia T. C., Tu C. Y., Chen Y. J., Wei Y. L., Yu M. C., Hsu S. C., Tsai S. L., Chen W. S., Yeh M. H., Yen C. J., Lapatinib-mediated cyclooxygenase-2 expression via epidermal growth factor receptor/HuR interaction enhances the aggressiveness of triple-negative breast cancer cells. Molecular Pharmacology 2013 83 4 857 869 10.1124/mol.112.082743
24. Chen Y. J., Chien P. H., Chen W. S., Chien Y. F., Hsu Y. Y., Wang L. Y., Chen J. Y., Lin C. W., Huang T. C., Yu Y. L., Hepatitis B virus-encoded X protein downregulates EGFR expression via inducing MicroRNA-7 in hepatocellular carcinoma cells. Evidence-Based Complementary and Alternative Medicine 2013 2013 10 682380 10.1155/2013/682380
25. Bolden J. E., Peart M. J., Johnstone R. W., Anticancer activities of histone deacetylase inhibitors. Nature Reviews Drug Discovery 2006 5 9 769 784 2-s2.0-33748451151 10.1038/nrd2133 (Pubitemid 44348499)
26. Linares A., Dalenc F., Balaguer P., Boulle N., Cavailles V., Manipulating protein acetylation in breast cancer: a promising approach in combination with hormonal therapies? Journal of Biomedicine and Biotechnology 2011 2011 15 2-s2.0-79251547681 10.1155/2011/856985 856985
27. Park S. Y., Jun J. I. A. E., Jeong K. J., Heo H. J., Sohn J. S., Lee H. Y., Park C. G., Kang J., Histone deacetylases 1, 6 and 8 are critical for invasion in breast cancer. Oncology Reports 2011 25 6 1677 1681 2-s2.0-79954535049 10.3892/or.2011.1236
28. Saji S., Kawakami M., Hayashi S. I., Yoshida N., Hirose M., Horiguchi S. I., Itoh A., Funata N., Schreiber S. L., Yoshida M., Toi M., Significance of HDAC6 regulation via estrogen signaling for cell motility and prognosis in estrogen receptor-positive breast cancer. Oncogene 2005 24 28 4531 4539 2-s2.0-22744446856 10.1038/sj.onc.1208646 (Pubitemid 41032616)
29. Bruzzese F., Leone A., Rocco M., Carbone C., Piro G., Caraglia M., Di Gennaro E., Budillon A., HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT. Journal of Cellular Physiology 2011 226 9 2378 2390 2-s2.0-79958719758 10.1002/jcp.22574
30. Chou C. W., Wu M. S., Huang W. C., Chen C. C., HDAC inhibition decreases the expression of EGFR in colorectal cancer cells. PLoS ONE 2011 6 3 2-s2.0-79953044882 10.1371/journal.pone.0018087 e18087
31. Gilbert R. E., Huang Q., Thai K., Advani S. L., Lee K., Yuen D. A., Connelly K. A., Advani A., Histone deacetylase inhibition attenuates diabetes-associated kidney growth: potential role for epigenetic modification of the epidermal growth factor receptor. Kidney International 2011 79 12 1312 1321 2-s2.0-79957815262 10.1038/ki.2011.39
32. Huang W. C., Hsu S. C., Huang S. J., Chen Y. J., Hsiao Y. C., Zhang W., Fidler I. J., Hung M. C., Exogenous expression of human SGLT1 exhibits aggregations in sodium dodecyl sulfate polyacrylamide gel electrophoresis. American Journal of Translational Research 2013 5 4 441 449
33. Huber K., Doyon G., Plaks J., Fyne E., Mellors J. W., Sluis-Cremer N., Inhibitors of histone deacetylases: correlation between isoform specificity and reactivation of HIV type 1 (HIV-1) from latently infected cells. Journal of Biological Chemistry 2011 286 25 22211 22218 2-s2.0-79959337704 10.1074/jbc.M110.180224
34. Richon V. M., Emiliani S., Verdin E., Webb Y., Breslow R., Rifkind R. A., Marks P. A., A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proceedings of the National Academy of Sciences of the United States of America 1998 95 6 3003 3007 2-s2.0-0032539890 10.1073/pnas.95.6.3003 (Pubitemid 28135844)
35. Gao Y. S., Hubbert C. C., Yao T. P., The microtubule-associated histone deacetylase 6 (HDAC6) regulates epidermal growth factor receptor (EGFR) endocytic trafficking and degradation. Journal of Biological Chemistry 2010 285 15 11219 11226 2-s2.0-77951223432 10.1074/jbc.M109.042754
36. Webster R. J., Giles K. M., Price K. J., Zhang P. M., Mattick J. S., Leedman P. J., Regulation of epidermal growth factor receptor signaling in human cancer cells by MicroRNA-7. Journal of Biological Chemistry 2009 284 9 5731 5741 2-s2.0-65549120766 10.1074/jbc.M804280200
37. Reddy S. D. N., Ohshiro K., Rayala S. K., Kumar R., MicroRNA-7, a homeobox D10 target, inhibits p21-activated kinase 1 and regulates its functions. Cancer Research 2008 68 20 8195 8200 2-s2.0-54249093368 10.1158/0008-5472.CAN-08-2103
38. Li X., Carthew R. W., A microRNA mediates EGF receptor signaling and promotes photoreceptor differentiation in the Drosophila eye. Cell 2005 123 7 1267 1277 2-s2.0-29244437868 10.1016/j.cell.2005.10.040 (Pubitemid 41821784)
39. Leary A. F., Drury S., Detre S., Pancholi S., Lykkesfeldt A. E., Martin L. A., Dowsett M., Johnston S. R. D., Lapatinib restores hormone sensitivity with differential effects on estrogen receptor signaling in cell models of human epidermal growth factor receptor 2-negative breast cancer with acquired endocrine resistance. Clinical Cancer Research 2010 16 5 1486 1497 2-s2.0-77649173208 10.1158/1078-0432.CCR-09-1764
40. Mayer I. A., Arteaga C. L., Does lapatinib work against HER2-negative breast cancers? Clinical Cancer Research 2010 16 5 1355 1357 2-s2.0-77649125821 10.1158/1078-0432.CCR-09-3223
41. Kim N. H., Kim S. N., Kim Y. K., Involvement of HDAC1 in E-cadherin expression in prostate cancer cells; its implication for cell motility and invasion. Biochemical and Biophysical Research Communications 2011 404 4 915 921 2-s2.0-79151482937 10.1016/j.bbrc.2010.12.081
42. Lei W., Zhang K., Pan X., Hu Y., Wang D., Yuan X., Shu G., Song J., Histone deacetylase 1 is required for transforming growth factor- β 1-induced epithelial-mesenchymal transition. International Journal of Biochemistry and Cell Biology 2010 42 9 1489 1497 2-s2.0-77955094541 10.1016/j.biocel.2010.05.006
43. Park S. Y., Jun J. I. A. E., Jeong K. J., Heo H. J., Sohn J. S., Lee H. Y., Park C. G., Kang J., Histone deacetylases 1, 6 and 8 are critical for invasion in breast cancer. Oncology Reports 2011 25 6 1677 1681 2-s2.0-79954535049 10.3892/or.2011.1236
44. Zhou Q., Shaw P. G., Davidson N. E., Inhibition of histone deacetylase suppresses EGF signaling pathways by destabilizing EGFR mRNA in ER-negative human breast cancer cells. Breast Cancer Research and Treatment 2009 117 2 443 451 2-s2.0-68949105725 10.1007/s10549-008-0148-5
45. Valenzuela-Fernández A., Cabrero J. R., Serrador J. M., Sánchez-Madrid F., HDAC6: a key regulator of cytoskeleton, cell migration and cell-cell interactions. Trends in Cell Biology 2008 18 6 291 297 2-s2.0-44649158252 10.1016/j.tcb.2008.04.003
46. Rhodes L. V., Nitschke A. M., Segar H. C., Martin E. C., Driver J. L., Elliott S., Nam S. Y., Li M., Nephew K. P., Burow M. E., Collins-Burow B. M., The histone deacetylase inhibitor trichostatin A alters microRNA expression profiles in apoptosis-resistant breast cancer cells. Oncology Reports 2012 27 1 10 16 2-s2.0-84855283939 10.3892/or.2011.1488
47. Bolleyn J., Fraczek J., Vinken M., Lizarraga D., Gaj S., Van Delft J. H. M., Rogiers V., Vanhaecke T., Effect of Trichostatin A on miRNA expression in cultures of primary rat hepatocytes. Toxicology In Vitro 2011 25 6 1173 1182 2-s2.0-79960906981 10.1016/j.tiv.2011.04.013
48. Zhao Z. N., Bai J. X., Zhou Q., Yan B., Qin W. W., Jia L. T., Meng Y. L., Jin B. Q., Yao L. B., Wang T., TSA suppresses miR-106b-93-25 cluster expression through downregulation of MYC and inhibits proliferation and induces apoptosis in human EMC. PLoS ONE 2012 7 9 e45133
49. Humphreys K. J., Cobiac L., Le Leu R. K., Van der Hoek M. B., Michael M. Z., Histone deacetylase inhibition in colorectal cancer cells reveals competing roles for members of the oncogenic miR-17-92 cluster. Molecular Carcinogenesis 2013 52 6 459 474 2-s2.0-84856441481 10.1002/mc.21879
50. Imesch P., Dedes K. J., Furlato M., Fink D., Fedier A., MLH1 protects from resistance acquisition by the histone deacetylase inhibitor trichostatin A in colon tumor cells. International Journal of Oncology 2009 35 3 631 640 2-s2.0-70349113558 10.3892/ijo-00000375